Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Gain Therapeutics Inc (GANX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GANX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 10.07% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.66M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 263009 | Beta 0.14 | 52 Weeks Range 0.89 - 4.04 | Updated Date 04/1/2025 |
52 Weeks Range 0.89 - 4.04 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.89 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -0.1875 | Actual -0.08 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -94.13% | Return on Equity (TTM) -263.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40664781 | Price to Sales(TTM) 925.92 |
Enterprise Value 40664781 | Price to Sales(TTM) 925.92 | ||
Enterprise Value to Revenue 138.33 | Enterprise Value to EBITDA -1.55 | Shares Outstanding 26525100 | Shares Floating 25224279 |
Shares Outstanding 26525100 | Shares Floating 25224279 | ||
Percent Insiders 5.01 | Percent Institutions 7.64 |
Analyst Ratings
Rating 4.5 | Target Price 7.33 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Gain Therapeutics Inc
Company Overview
History and Background
Gain Therapeutics Inc. was founded in 2017. It is a clinical-stage biotechnology company focused on developing small molecule therapeutics targeting disease-modifying targets to treat genetically defined neurological diseases and cancer.
Core Business Areas
- Structural Biology Based Drug Discovery: Developing small molecule therapeutics targeting misfolded proteins using their proprietary SEE-Txu2122 (Structurally Enabled Enzyme Enhancer) platform.
- Neurological Disease Focus: Specifically targeting genetically defined neurological diseases such as GBA1 Parkinson's Disease and neuronopathic Gaucher disease (nGD).
- Cancer Focus: Developing cancer drugs that target oncogenic drivers
Leadership and Structure
Gain Therapeutics is led by CEO Matthias Alder. The company's organizational structure includes scientific, clinical development, and administrative teams.
Top Products and Market Share
Key Offerings
- GT-02287 (GBA1 Parkinson's Disease): A small molecule SEE-Txu2122 compound designed to allosterically modulate glucocerebrosidase (GCase), improving its folding and trafficking to lysosomes, where it is critical for lipid metabolism. Currently in Phase 1 clinical trials. Competition includes enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Market share is not yet applicable given clinical trial stage.
- GT-02329 (nGD): A small molecule SEE-Txu2122 compound for neuronopathic Gaucher disease (nGD), also targetting GCase. In preclinical development. Competition includes enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Market share is not yet applicable given preclinical stage.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and subject to rapid technological change. It includes companies developing therapeutics for a wide range of diseases, including neurological disorders and cancer.
Positioning
Gain Therapeutics is positioned as an innovator in developing small molecule therapies for genetically defined diseases, particularly focusing on neurological disorders. Their SEE-Txu2122 platform provides a potential competitive advantage.
Total Addressable Market (TAM)
The total addressable market for Parkinson's disease and Gaucher disease is significant, estimated at billions of dollars. Gain Therapeutics aims to capture a share of this market by providing disease-modifying therapies rather than just symptomatic relief.
Upturn SWOT Analysis
Strengths
- Proprietary SEE-Txu2122 platform
- Focus on disease-modifying therapies
- Strong intellectual property portfolio
- Experienced leadership team
- Targeting unmet needs in genetically defined diseases
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Limited commercial infrastructure
- Small company size relative to competitors
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new disease areas
- Orphan drug designation for targeted therapies
- Advancements in understanding protein folding and trafficking
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- SANOY
- AMGN
- AGEN
Competitive Landscape
Gain Therapeutics' advantages lie in its SEE-Txu2122 platform and focus on disease-modifying therapies. Its disadvantages are its early-stage development and limited resources compared to larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is related to stock market conditions and pipeline advancements and can be calculated using historical stock market data
Future Projections: Future projections depend on clinical trial outcomes, regulatory approvals, and market adoption, and would be published by market analysts if any.
Recent Initiatives: Recent strategic initiatives include advancing their clinical programs, expanding their pipeline, and securing partnerships.
Summary
Gain Therapeutics is a clinical-stage biotechnology company with a proprietary platform and focus on genetically defined diseases. The company's strengths include its innovative technology and experienced leadership, while its weaknesses relate to its early stage of development and limited resources. Positive clinical trial results and strategic partnerships are crucial for future growth. The company is exposed to clinical trial risks and competition from established therapies.
Similar Companies
- VRDN
- RVMD
- IONS
- CRSP
Sources and Disclaimers
Data Sources:
- Gain Therapeutics Inc. SEC Filings
- Gain Therapeutics Inc. Investor Relations
- Industry Reports
- Analyst Reports (if any)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gain Therapeutics Inc
Exchange NASDAQ | Headquaters Bethesda, MD, United States | ||
IPO Launch date 2021-03-18 | President, CEO & Director Mr. Gene Mack M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 29 | Website https://www.gaintherapeutics.com |
Full time employees 29 | Website https://www.gaintherapeutics.com | ||
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.